MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL, David HYNEK, Ondrej ZITKA, Zbynek HEGER, Pavel KOPEL, Vojtech ADAM and Vedran MILOSAVLJEVIC. Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism. Materials Today Bio. AMSTERDAM: Elsevier, 2023, vol. 19, Apr, p. 1-14. ISSN 2590-0064. Available from: https://dx.doi.org/10.1016/j.mtbio.2023.100570.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism
Authors MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL, David HYNEK, Ondrej ZITKA, Zbynek HEGER, Pavel KOPEL, Vojtech ADAM and Vedran MILOSAVLJEVIC (guarantor).
Edition Materials Today Bio, AMSTERDAM, Elsevier, 2023, 2590-0064.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 20601 Medical engineering
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.200 in 2022
RIV identification code RIV/00216224:90242/23:00133762
Doi http://dx.doi.org/10.1016/j.mtbio.2023.100570
UT WoS 000931958900001
Keywords in English Platinum nanoparticles; Cisplatin; CAM assay; Breast cancer; Amino acids metabolism; TCA cycle
Tags CF CRYO, ne MU, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 11/4/2024 23:14.
Abstract
The combination of in ovo and ex ovo chorioallantoic membrane (CAM) assay provides an excellent platform which extends its relevance in studying carcinogenesis to the field of screening of anticancer activity of platinum nanoparticles (PtNPs) and further study of the amino acids' fluctuations in liver and brain. PtNPs are promising candidates for replacing cisplatin (CDDP); however, insufficient data of their antitumor efficiency and activity on the cancer-related amino acid metabolism are available, and the assessment of the in vivo performance has barely scratched the surface. Herein, we used CAM assay as in vivo model for screening of novel therapeutic modalities, and we conducted a comparative study of the effects of CDDP and polyvinylpyrrolidone coated PtNPs on MDA-MB-231 breast cancer xenograft. PtNPs showed a higher efficiency to inhibit the tumor growth and metastasis compared to CDDP. The amino acids profiling in the MDA-MB-231 cells revealed that the PtNPs had an overall depleting effect on the amino acids content. Noteworthy, more side effects to amino acid metabolism were deduced from the depletion of the amino acids in tumor, brain, and liver upon CDDP treatment. Different sets of enzymes of the tricarboxylic acid (TCA) cycle were targeted by PtNPs and CDDP, and while mRNA encoding multiple enzymes was downregulated by PtNPs, the treatment with CDDP affected only two TCA enzymes, indicating a different mechanism of action. Taken together, CAM assay represents and invaluable model, demonstrating the PtNPs capability of repressing angiogenesis, decrease amino acid contents and disrupt the TCA cycle.
Links
90242, large research infrastructuresName: CIISB III
PrintDisplayed: 23/7/2024 22:16